Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning
Executive Summary
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling
You may also be interested in...
GSK Temporarily Pulls sNDA For Avodart
GSK has temporarily pulled its supplemental application for Avodart for reducing the risk of prostate cancer, in order to update the data in the sNDA.
Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data
Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data